Investigational New Drugs

, Volume 28, Issue 5, pp 690–693 | Cite as

Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma

  • Judith Michels
  • Nathalie Lassau
  • Marine Gross-Goupil
  • Christophe Massard
  • Arnaud Mejean
  • Bernard Escudier


Sunitinib is an oral antityrosine kinase inhibitor that has antiangiogenic and antitumor activities. It has been approved for the treatment of advanced RCC and for imatinib-refractory gastrointestinal stromal tumors (GIST). Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome.


Sunitinib Renal cell carcinoma Tumor lysis syndrome 



The authors thank Lorna Saint Ange for editing.


  1. 1.
    Lassau N, Chami L, Benatsou B, Peronneau P, Roche A (2007) Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol 17(6):89–98. doi: 10.1007/s10406-007-0233-6 CrossRefGoogle Scholar
  2. 2.
    Baeksgaard L, Sørensen JB (2003) Acute tumor lysis syndrome in solid tumors–a case report and review of the literature. Cancer Chemother Pharmacol 51(3):187–192PubMedGoogle Scholar
  3. 3.
    Teo WY, Loh TF, Tan AM (2007) Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature. Ann Acad Med Singapore 36(8):679–683, ReviewPubMedGoogle Scholar
  4. 4.
    Lin CJ, Chen HH, Hsieh RK, Chen YC, Wu CJ (2009) Acute tumor lysis syndrome in a hemodialysis patient with diffuse large B cell lymphoma. Med Oncol 26(1):93–95. doi: 10.1007/s12032-008-9064-0 CrossRefPubMedGoogle Scholar
  5. 5.
    Rényi I, Bárdi E, Udvardi E, Kovács G, Bartyik K, Kajtár P, Masát P, Nagy K, Galántai I, Kiss C (2007) Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin’s lymphoma. Pathol Oncol Res 13(1):57–62. doi: 10.1007/BF02893442 CrossRefPubMedGoogle Scholar
  6. 6.
    Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25(7):884–896, Review. doi: 10.1200/JCO.2006.06.3602 CrossRefPubMedGoogle Scholar
  7. 7.
    Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. doi: 10.1056/NEJMoa065044 CrossRefPubMedGoogle Scholar
  8. 8.
    Nicholaou T, Wong R, Davis ID (2007) Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet 369(9577):1923–1924. doi: 10.1016/S0140-6736(07)60903-9 CrossRefPubMedGoogle Scholar
  9. 9.
    Saylor PJ, Reid TR (2007) Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol 25(23):3544–3546. doi: 10.1200/JCO.2007.12.0790 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Judith Michels
    • 1
  • Nathalie Lassau
    • 2
  • Marine Gross-Goupil
    • 1
  • Christophe Massard
    • 1
  • Arnaud Mejean
    • 3
  • Bernard Escudier
    • 1
    • 4
  1. 1.Institut Gustave RoussyDépartement de MédecineVillejuifFrance
  2. 2.Institut Gustave RoussyDépartement d’ImagerieVillejuifFrance
  3. 3.Service de Chirurgie Urologique, Hopital NeckerParisFrance
  4. 4.Institut Gustave-RoussyVillejuifFrance

Personalised recommendations